Baquiloprim-d6

Baquiloprim-d6 is deuterium labeled Baquiloprim. Baquiloprim, an antibiotic, is a selective inhibitor of bacterial dihydrofolate reductases. Baquiloprim possesses in vitro bacteriostatic activity against both Gram-negative and Gram-positive bacteria[1][2].

Product Specifications

CAS Number

[1228182-50-0]

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

Antibiotic; Bacterial; Isotope-Labeled Compounds

Type

Isotope-Labeled Compounds

Related Pathways

Anti-infection; Others

Applications

COVID-19-immunoregulation

Field of Research

Infection

Solubility

10 mM in DMSO

Smiles

[2H]C([2H])([2H])N(C([2H])([2H])[2H])C(C(N=CC=C1)=C1C(CC2=CN=C(N)N=C2N)=C3)=C3C

Molecular Formula

C17H14D6N6

Molecular Weight

314.42

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Lewicki J, et, al. Oral bioavailability and pharmacokinetics of baquiloprim in dwarf goats. Res Vet Sci. 1995 May;58 (3) :268-71.|[3]White DG, et, al. Comparison of danofloxacin with baquiloprim/sulphadimidine for the treatment of experimentally induced Escherichia coli diarrhoea in calves. Vet Rec. 1998 Sep 5;143 (10) :273-6.